UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Two decades of targeted therapies in acute myeloid leukemia

Leukemia, 2021-03, Vol.35 (3), p.651-660

2021

Volltextzugriff (PDF)

Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation

BMC cancer, 2017-11, Vol.17 (1), p.739-739, Article 739

2017

Volltextzugriff (PDF)

Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment

Current oncology reports, 2022-11, Vol.24 (11), p.1387-1400

2022

Volltextzugriff (PDF)

Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands

Leukemia, 2021-11, Vol.35 (11), p.3291-3294

2021

Volltextzugriff (PDF)

Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia

Leukemia, 2024-03, Vol.38 (3), p.630-639

2024

Volltextzugriff (PDF)

Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017

Leukemia, 2020-12, Vol.34 (12), p.3408-3412

2020

Volltextzugriff (PDF)

Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients

Leukemia, 2018-10, Vol.32 (10), p.2299-2303

2018

Volltextzugriff (PDF)

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON)

European journal of cancer (1990), 2013-10, Vol.49 (15), p.3242-3246

2013

Volltextzugriff (PDF)

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

Pharmaceutics, 2023-10, Vol.15 (11), p.2535

2023

Volltextzugriff (PDF)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

Cancers, 2022-07, Vol.14 (14), p.3456

2022

Volltextzugriff (PDF)

Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile

Bone marrow transplantation (Basingstoke), 2020-11, Vol.55 (11), p.2188-2192

2020

Volltextzugriff (PDF)

Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity

Supportive care in cancer, 2024-09, Vol.32 (9), p.579, Article 579

2024

Volltextzugriff (PDF)

MRD Tailored Therapy in AML: What We Have Learned So Far

Frontiers in oncology, 2021-01, Vol.10, p.603636-603636

2021

Volltextzugriff (PDF)

The wider perspective: twenty years of clinical trials in myelodysplastic syndromes

British journal of haematology, 2022-01, Vol.196 (2), p.329-335

2022

Volltextzugriff (PDF)

Correction: Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017

Leukemia, 2020-12, Vol.34 (12), p.3440-3440

2020

Volltextzugriff (PDF)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib

European journal of clinical pharmacology, 2020-09, Vol.76 (9), p.1213-1226

2020

Volltextzugriff (PDF)

A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts

Biomedicines, 2022-11, Vol.10 (12), p.3063

2022

Volltextzugriff (PDF)

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018

British journal of haematology, 2022-03, Vol.196 (5), p.1219-1224

2022

Volltextzugriff (PDF)

Dose selection of novel anticancer drugs: exposing the gap between selected and required doses

The lancet oncology, 2024-08, Vol.25 (8), p.e340-e351

2024

Volltextzugriff (PDF)

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients

European journal of haematology, 2024-11, Vol.113 (5), p.606-613

2024

Volltextzugriff (PDF)

Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling

European journal of clinical pharmacology, 2019-06, Vol.75 (6), p.825-829

2019

Volltextzugriff (PDF)

TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study)

European journal of haematology, 2021-09, Vol.107 (3), p.364-369

2021

Volltextzugriff (PDF)

1 – 25 von 490

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(462)
Mit Volltextzugriff
(440)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Two decades of targeted therapies in acute myeloid leukemia

Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment

Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands

Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia

Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017

Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON)

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile

Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity

MRD Tailored Therapy in AML: What We Have Learned So Far

The wider perspective: twenty years of clinical trials in myelodysplastic syndromes

Correction: Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib

A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018

Dose selection of novel anticancer drugs: exposing the gap between selected and required doses

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients

Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling

TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study)

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

Suchergebnisse filtern